StockNews.com Initiates Coverage on Alimera Sciences (NASDAQ:ALIM)

Stock analysts at StockNews.com began coverage on shares of Alimera Sciences (NASDAQ:ALIM) in a note issued to investors on Sunday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

ALIM has been the topic of a number of other reports. Alliance Global Partners reaffirmed a “neutral” rating on shares of Alimera Sciences in a research report on Tuesday, June 25th. Maxim Group restated a “hold” rating on shares of Alimera Sciences in a report on Tuesday, June 25th. Finally, HC Wainwright cut Alimera Sciences from a “buy” rating to a “neutral” rating and set a $6.00 target price for the company. in a report on Tuesday, June 25th.

Alimera Sciences Price Performance

Shares of ALIM stock opened at $5.54 on Friday. The stock has a 50 day moving average price of $5.56 and a 200 day moving average price of $4.45. Alimera Sciences has a 52-week low of $2.61 and a 52-week high of $5.65. The company has a debt-to-equity ratio of 1.80, a quick ratio of 2.62 and a current ratio of 2.79. The firm has a market capitalization of $290.24 million, a P/E ratio of -3.53 and a beta of 1.25.

Alimera Sciences (NASDAQ:ALIM) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). The company had revenue of $27.00 million for the quarter, compared to analysts’ expectations of $25.76 million. Alimera Sciences had a negative net margin of 14.74% and a negative return on equity of 33.70%. As a group, sell-side analysts predict that Alimera Sciences will post -0.13 earnings per share for the current year.

Hedge Funds Weigh In On Alimera Sciences

Hedge funds and other institutional investors have recently modified their holdings of the business. Deltec Asset Management LLC purchased a new position in shares of Alimera Sciences in the 2nd quarter worth approximately $690,000. Vanguard Group Inc. grew its holdings in Alimera Sciences by 61.1% in the first quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock worth $4,077,000 after purchasing an additional 396,506 shares during the last quarter. Ancora Advisors LLC acquired a new position in shares of Alimera Sciences during the first quarter worth $915,000. Fifth Lane Capital LP purchased a new stake in shares of Alimera Sciences during the 1st quarter valued at $83,000. Finally, Hillsdale Investment Management Inc. acquired a new stake in shares of Alimera Sciences in the 1st quarter worth $169,000. 99.83% of the stock is currently owned by institutional investors.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).